The scientific basis of combination therapy for chronic hepatitis B functional cure
Functional cure of chronic hepatitis B (CHB)—or hepatitis B surface antigen (HBsAg) loss
after 24 weeks off therapy—is now the goal of treatment, but is rarely achieved with current …
after 24 weeks off therapy—is now the goal of treatment, but is rarely achieved with current …
Recent progress and future prospective in HBV cure by CRISPR/Cas
YC Yang, HC Yang - Viruses, 2021 - mdpi.com
Hepatitis B virus (HBV) infection remains an important issue of global public health.
Although current antiviral therapy has dramatically reduced the mortality and morbidity of …
Although current antiviral therapy has dramatically reduced the mortality and morbidity of …
APASL guidance on stop** nucleos (t) ide analogues in chronic hepatitis B patients
Chronic hepatitis B virus (HBV) infection is currently incurable. Long-term treatment with
potent and safe nucleos (t) ide analogs (NAs) can reduce hepatocellular carcinoma (HCC) …
potent and safe nucleos (t) ide analogs (NAs) can reduce hepatocellular carcinoma (HCC) …
Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg‐negative chronic …
Reliable predictors of outcomes after treatment discontinuation in HBeAg‐negative chronic
hepatitis B (CHB) patients have not been established. We investigated the role of hepatitis B …
hepatitis B (CHB) patients have not been established. We investigated the role of hepatitis B …
Hepatitis B surface antigen, core‐related antigen and HBV RNA: predicting clinical relapse after NA therapy discontinuation
Abstract Background & Aims The safe discontinuation of nucleos (t) ide analogue therapy
remains challenging in chronic hepatitis B. We investigated the potential role of quantitative …
remains challenging in chronic hepatitis B. We investigated the potential role of quantitative …
Significance of serum HBV RNA in non‐cirrhotic HBeAg‐negative chronic hepatitis B patients who discontinue effective antiviral therapy
M Papatheodoridi, E Papachristou… - Journal of Viral …, 2022 - Wiley Online Library
HBV RNA is considered as a promising predictor in patients who discontinue nucleos (t) ide
analogues (NAs). We determined HBV RNA levels in non‐cirrhotic HBeAg‐negative patients …
analogues (NAs). We determined HBV RNA levels in non‐cirrhotic HBeAg‐negative patients …
[HTML][HTML] Quantitative HBV Core Antibodies as a Prognostic Marker for HBeAg Seroclearance: A Systematic Review with Meta-Analysis
During chronic hepatitis B virus (HBV) infection, the seroclearance of hepatitis B e antigen
(HBeAg) is an important event and a significant surrogate endpoint of all current therapeutic …
(HBeAg) is an important event and a significant surrogate endpoint of all current therapeutic …
Emerging diagnostic tools to decide when to discontinue nucleos (t) ide analogues in chronic hepatitis B
The aim of this review is to outline emerging biomarkers that can serve as diagnostic tools to
identify non-cirrhotic chronic hepatitis B (CHB) patients who could safely discontinue …
identify non-cirrhotic chronic hepatitis B (CHB) patients who could safely discontinue …
Hepatocellular carcinoma after treatment cessation in non‐cirrhotic HBeAg‐negative chronic hepatitis B: A multicentre cohort study
Abstract Background and Aims Scarce data exist on the effect of nucleos (t) ide analogue
(NA) discontinuation on hepatocellular carcinoma (HCC) risk in HBeAg‐negative chronic …
(NA) discontinuation on hepatocellular carcinoma (HCC) risk in HBeAg‐negative chronic …
[HTML][HTML] Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment
Droplet digital PCR is an innovative and promising approach for highly sensitive
quantification of nucleic acids that is being increasingly used in the field of clinical virology …
quantification of nucleic acids that is being increasingly used in the field of clinical virology …